Associated Genetic Biomarkers
NCI Definition: A melanoma that arises from a mucosal site. 
Mucosal melanomas most frequently harbor alterations in NF1, TP53, KIT, CDKN2A, and ATRX .
TP53 Mutation, KIT Mutation (somatic), KIT Mutation, TP53 c.217-c.1178 Missense, and TP53 c.142-c.212 Missense are the most common alterations in mucosal melanoma .
There are 5 clinical trials for mucosal melanoma, of which 4 are open and 1 is completed or closed. Of the trials that contain mucosal melanoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open).
BRAF and KIT are the most frequent gene inclusion criteria for mucosal melanoma clinical trials .
Ipilimumab, nivolumab, and cobimetinib are the most common interventions in mucosal melanoma clinical trials.
Significant Genes in Mucosal Melanoma
BRAF is mutated in 12.28% of mucosal melanoma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) .
Cobimetinib and vemurafenib are the most frequent therapies in mucosal melanoma trials with BRAF mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.